Kronik Hepatit C'de Pegile interferon Alfa ve Ribavirin Tedavisi Esnasrnda Gelisen Akut Bruselloz; Olgu Sunumu

Öz

Anahtar Kelimeler

• -

Kronik Hepatit C'de Pegile interferon Alfa ve Ribavirin Tedavisi Esnasrnda Gelisen Akut Bruselloz; Olgu Sunumu

Öz

Pegile interferon kullanımına bağlı enfeksiyona duyarlılıkta artış gözlenmekte ve gelişen yan etkiler birçok enfeksiyon hastalığının klinik bulguları ile karışabilnıektedir. Multisistem hastalık olan bruselloz. ülkemizde endemiktir. Birçok organ ve sistemi tutan sistemik bir enfeksiyon olması nedeni ile klinik bulgu ve semptomlar genis bir spektrum oluşturur. Raporda kronik hepatit C tanısı ile izlenen hastada, PEG-lFN alfa ve ribaıirin tcdaı isi esnasında akut bruselloz gelişimi sunulmuştur

Anahtar Kelimeler

• Kronik hepatit C. Bruselloz

Kaynakça

1. Lauer G. Walker BD. Hepatitis C virus infection. N Engl J Med 20011345: 41-52
2. Annual report of the US scientific registry for trans- plant recipients and the organ procurement and trans— plantation network-transplant data: 1988-1994. Rich— mond, VA: United Network for Organ Sharing and the Division of Organ Transplantation. Bureau of Health Resources Development.
3. Di Bisceglie A, Hoofnagle J. Optimal therapy of hepatitis C. Hepatology 20()2:36:l2l-7.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
5. Gençer S, Özer S. Spontaneous bacterial peritonitis caused by Brucella melitensis. Scand J Infect Dis 2003;35:341-3
6. FASL. EASL International Consensus Conference on Hepatitis C, Paris. 26-28 February 1999, Consensus Statement. European Association for the Study ofthe Liver. .l Hepatol l999;30:956-61
7. Pııoti M. Babudieri S, Rezza G. et al. Use of pegy- lated interferons is associated with an increased inci- dence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Anti- viral Therapy 2004:9z627-30
8. Chutaputti A. Adverse effects and other safety as- pects of the hepatitis C antivirals. J Gastroenterol Hepatol 2000:15(Suppl):E156-63

9. Leblebicioğlu l—l. Kronik hepatit C'de güncel tedavi. ANKEM Derg 2006:20(2):208-12.
10. Hatipoğlu ÇA, Yetkin A, Ertem GT. Tülek N. Un- usual clinical presentations of brucellosis. Scand J In— fect Dis 2004;36:694-7
11. Young EJ. Brucella species, ppz2669-74 ln: Mandell GL, Bennett JE. Dolin R (eds). Mandell. Douglas. and Bennett’s Principles and Practice of Infectious Diseases 2005. 6th ed. Churchill Livingstone. Phila- delphia.
12. Crosby E, Liosa L, Miro QM. Carrillo P. Gotuzzo E. Hematologic changes in brucellosis. J lnfcet Dis 1984; 150:419-24
13. Di Mario A. Sica S, Zini G, Salutari P. Leone G. Mi— croangiopathic hemolytic anemia and severe throm- bocytopenia in Brucella infection. Ann Hematol 1995; 70:59-60
14. Strader DB, Wright T. Thomas DL. Seeff LB. Seeff LB. Diagnosis, management. and treatment of hepati- tis C. Hepatology 2004:39(4):l 147-71.
15. Manns MP. McHutchison JG. Gordon SC. et al. Peginterferon alfa—lb plus ribavirin compared with interferon alfa-Zb plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65.